ORKA
Oruka Therapeutics, Inc.$86.70-0.77 (-0.88%)Prev Close$87.47·MCap$3.25B·P/E—·Vol441.8K·Yield0.22%
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
25
$315.24M
◆
Net Activity
Net Seller
$315.24M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Oruka Therapeutics, Inc. (ORKA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 25 insider sales totaling $315.24M. The most recent insider transaction was by Agarwal Arjun (officer: Senior Vice President, Finance), who sold $821.3K worth of shares on Jul 13, 2026. Oruka Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.25B.
ORKA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 9,699 | $84.67 | $821.3K | 21,268-31% |
| Jul 1, 2026 | Fairmount Funds Management LLC | director, 10 percent owner: | Sell | 3,553,410 | $84.43 | $300.01M9.5% OS | 1,131,954-76% |
| Jul 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $94.42 | $472.1K | 239,147 |
| Jun 22, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 1,587 | $80.95 | $128.5K | 16,011 |
| Jun 15, 2026 | Quinlan Paul T | officer: General Counsel | Sell | 733 | $69.69 | $51.1K | 31,034 |
| Jun 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,947 | $69.28 | $550.6K | 39,029 |
| Jun 15, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 9,854 | $69.72 | $687.0K | 24,894-28% |
| Jun 15, 2026 | Klein Lawrence Otto | director, officer: Chief Executive Officer | Sell | 1,729 | $69.69 | $120.5K | 925,580 |
| Jun 15, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 600 | $69.69 | $41.8K | 236,384 |
| Jun 12, 2026 | Dambkowski Carl | director | Sell | 35,000 | $70.13 | $2.45M | 51,326-41% |
| May 22, 2026 | Dambkowski Carl | director | Sell | 105,000 | $58.97 | $6.19M | 140,425-43% |
| May 18, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 10,290 | $59.07 | $607.8K | 22,506-31% |
| May 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $61.85 | $432.9K | 35,577 |
| May 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $63.88 | $319.4K | 239,784 |
| Apr 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $66.12 | $462.8K | 36,150 |
| Mar 17, 2026 | Quinlan Paul T | officer: General Counsel | Sell | 733 | $41.30 | $30.3K | 31,767 |
| Mar 17, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 395 | $41.30 | $16.3K | 18,863 |
| Mar 17, 2026 | Klein Lawrence Otto | director, officer: Chief Executive Officer | Sell | 1,729 | $41.30 | $71.4K | 927,309 |
| Mar 17, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 600 | $41.30 | $24.8K | 236,984 |
| Mar 17, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,641 | $40.91 | $312.6K | 38,097 |
| Mar 2, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $33.56 | $167.8K | 240,259 |
| Feb 17, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 14,000 | $32.37 | $453.1K | 34,954-29% |
| Jan 16, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $31.81 | $222.7K | 4,137-63% |
| Jan 2, 2026 | Sandler Laura Lee | Chief Operating Officer | Sell | 13,000 | $28.52 | $370.8K | 209,336 |
| Dec 19, 2025 | Goncalves Joana | Chief Medical Officer | Sell | 7,000 | $30.61 | $214.3K | 7,877-47% |
| Feb 27, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 122,882 | $11.45 | $1.41M | 4,148,428 | |
| May 25, 2022 | Funicular Fund, LP | Buy | 85,262 | $2.32 | $197.4K | 2,580,452 | |
| May 20, 2022 | Funicular Fund, LP | Buy | 13,073 | $2.30 | $30.1K | 2,495,190 | |
| May 16, 2022 | Funicular Fund, LP | Buy | 84,836 | $2.29 | $194.1K | 2,482,117 | |
| May 11, 2022 | Funicular Fund, LP | Buy | 45,575 | $2.28 | $104.1K | 2,397,281 | |
| May 9, 2022 | Funicular Fund, LP | Buy | 124,122 | $2.28 | $282.6K | 2,351,706 | |
| May 2, 2022 | Funicular Fund, LP | Buy | 33,614 | $2.31 | $77.7K | 2,227,584 | |
| Apr 27, 2022 | Funicular Fund, LP | Buy | 13,751 | $2.29 | $31.5K | 2,193,970 | |
| Apr 20, 2022 | Funicular Fund, LP | Buy | 9,119 | $2.31 | $21.1K | 2,180,219 | |
| Apr 14, 2022 | Funicular Fund, LP | Buy | 17,410 | $2.33 | $40.5K | 2,171,100 | |
| Apr 12, 2022 | Funicular Fund, LP | Buy | 104,713 | $2.32 | $242.7K | 2,153,690 | |
| Apr 7, 2022 | Funicular Fund, LP | Buy | 103,984 | $2.31 | $239.8K | 2,048,977 | |
| Apr 4, 2022 | Funicular Fund, LP | Buy | 122,342 | $2.26 | $276.3K | 1,944,993 | |
| Nov 23, 2021 | Ozeroff Christopher David | S.V.P., General Counsel | Buy | 50,000 | $2.26 | $113.2K | 50,970New Position |
| May 13, 2021 | CONWAY ROBERT E | Director | Buy | 10,000 | $3.19 | $31.9K | 50,000+25% |
| May 6, 2021 | CONWAY ROBERT E | Director | Buy | 10,000 | $3.23 | $32.3K | 40,000+33% |
ORKA Insider Buying Activity
The following table shows recent insider purchases of Oruka Therapeutics, Inc. (ORKA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 27, 2025 | Venrock Healthcare Capital Partners III, L.P. | Buy | 122,882 | $11.45 | $1.41M | 4,148,428 | |
| May 25, 2022 | Funicular Fund, LP | Buy | 85,262 | $2.32 | $197.4K | 2,580,452 | |
| May 20, 2022 | Funicular Fund, LP | Buy | 13,073 | $2.30 | $30.1K | 2,495,190 | |
| May 16, 2022 | Funicular Fund, LP | Buy | 84,836 | $2.29 | $194.1K | 2,482,117 | |
| May 11, 2022 | Funicular Fund, LP | Buy | 45,575 | $2.28 | $104.1K | 2,397,281 | |
| May 9, 2022 | Funicular Fund, LP | Buy | 124,122 | $2.28 | $282.6K | 2,351,706 | |
| May 2, 2022 | Funicular Fund, LP | Buy | 33,614 | $2.31 | $77.7K | 2,227,584 | |
| Apr 27, 2022 | Funicular Fund, LP | Buy | 13,751 | $2.29 | $31.5K | 2,193,970 | |
| Apr 20, 2022 | Funicular Fund, LP | Buy | 9,119 | $2.31 | $21.1K | 2,180,219 | |
| Apr 14, 2022 | Funicular Fund, LP | Buy | 17,410 | $2.33 | $40.5K | 2,171,100 | |
| Apr 12, 2022 | Funicular Fund, LP | Buy | 104,713 | $2.32 | $242.7K | 2,153,690 | |
| Apr 7, 2022 | Funicular Fund, LP | Buy | 103,984 | $2.31 | $239.8K | 2,048,977 | |
| Apr 4, 2022 | Funicular Fund, LP | Buy | 122,342 | $2.26 | $276.3K | 1,944,993 | |
| Nov 23, 2021 | Ozeroff Christopher David | S.V.P., General Counsel | Buy | 50,000 | $2.26 | $113.2K | 50,970New Position |
| May 13, 2021 | CONWAY ROBERT E | Director | Buy | 10,000 | $3.19 | $31.9K | 50,000+25% |
| May 6, 2021 | CONWAY ROBERT E | Director | Buy | 10,000 | $3.23 | $32.3K | 40,000+33% |
ORKA Insider Selling Activity
The following table shows recent insider sales of Oruka Therapeutics, Inc. (ORKA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 13, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 9,699 | $84.67 | $821.3K | 21,268-31% |
| Jul 1, 2026 | Fairmount Funds Management LLC | director, 10 percent owner: | Sell | 3,553,410 | $84.43 | $300.01M9.5% OS | 1,131,954-76% |
| Jul 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $94.42 | $472.1K | 239,147 |
| Jun 22, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 1,587 | $80.95 | $128.5K | 16,011 |
| Jun 15, 2026 | Quinlan Paul T | officer: General Counsel | Sell | 733 | $69.69 | $51.1K | 31,034 |
| Jun 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,947 | $69.28 | $550.6K | 39,029 |
| Jun 15, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 9,854 | $69.72 | $687.0K | 24,894-28% |
| Jun 15, 2026 | Klein Lawrence Otto | director, officer: Chief Executive Officer | Sell | 1,729 | $69.69 | $120.5K | 925,580 |
| Jun 15, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 600 | $69.69 | $41.8K | 236,384 |
| Jun 12, 2026 | Dambkowski Carl | director | Sell | 35,000 | $70.13 | $2.45M | 51,326-41% |
| May 22, 2026 | Dambkowski Carl | director | Sell | 105,000 | $58.97 | $6.19M | 140,425-43% |
| May 18, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 10,290 | $59.07 | $607.8K | 22,506-31% |
| May 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $61.85 | $432.9K | 35,577 |
| May 1, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $63.88 | $319.4K | 239,784 |
| Apr 15, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $66.12 | $462.8K | 36,150 |
| Mar 17, 2026 | Quinlan Paul T | officer: General Counsel | Sell | 733 | $41.30 | $30.3K | 31,767 |
| Mar 17, 2026 | Agarwal Arjun | officer: Senior Vice President, Finance | Sell | 395 | $41.30 | $16.3K | 18,863 |
| Mar 17, 2026 | Klein Lawrence Otto | director, officer: Chief Executive Officer | Sell | 1,729 | $41.30 | $71.4K | 927,309 |
| Mar 17, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 600 | $41.30 | $24.8K | 236,984 |
| Mar 17, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,641 | $40.91 | $312.6K | 38,097 |
| Mar 2, 2026 | Sandler Laura Lee | officer: Chief Operating Officer | Sell | 5,000 | $33.56 | $167.8K | 240,259 |
| Feb 17, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 14,000 | $32.37 | $453.1K | 34,954-29% |
| Jan 16, 2026 | Goncalves Joana | officer: Chief Medical Officer | Sell | 7,000 | $31.81 | $222.7K | 4,137-63% |
| Jan 2, 2026 | Sandler Laura Lee | Chief Operating Officer | Sell | 13,000 | $28.52 | $370.8K | 209,336 |
| Dec 19, 2025 | Goncalves Joana | Chief Medical Officer | Sell | 7,000 | $30.61 | $214.3K | 7,877-47% |
ORKA Insiders
Similar Stocks to ORKA
VRTX
Vertex Pharmaceuticals Incorporated
$477.45+0.18%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$661.90+0.88%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$279.67-0.60%
$43.19B
RVMD
Revolution Medicines, Inc.
$184.79-0.09%
$40.34B
MRNA
Moderna, Inc.
$67.55+0.16%
$27.09B
INSM
Insmed Incorporated
$109.58-0.48%
$25.06B
INCY
Incyte Corporation
$114.75-0.11%
$23.32B
UTHR
United Therapeutics Corporation
$530.82+0.79%
$23.22B